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Heart rate in epidemiological studies
Over the last 25 years numerous reports demonstrated a 
significant association between resting heart rate and all-
cause mortality in addition to cardiovascular mortality.
Observational studies, such as the Framingham Heart 
study or the French IPC study showed that a high resting 
heart rate is associated with an increase in cardiovascular 
mortality in the general population1,2 and this has also been 
demonstrated in hypertension, acute myocardial infarction 
and heart failure or left ventricular dysfunction.
Heart rate in coronary heart disease
A high resting heart rate in patients with known 
coronary artery disease is associated with an increase in 
cardiovascular mortality e.g. in the CASS-study of 24 913 
patients with stable coronary artery disease followed up for 
a mean of 14.7 years.3 Both all-cause and cardiovascular 
mortality were directly related to resting heart rate at study 
entry. This predictive capacity was independent of all 
cardiovascular risk factors, left ventricular ejection fraction 
and number of diseased coronary vessels.
Similarly, a high resting heart rate in patients presenting 
with a ST-segment elevation myocardial infarction (STEMI) 
increases the mortality.
It is possible that a high resting heart rate can increase shear 
stress and increase atherosclerostic plaque vulnerability 
and so cause plaque rupture.4
CRUSADE is a large observational study designed to 
promote evidence-based treatment of acute coronary 
syndrome. In 139 194 patients with a non-ST-segment 
elevated acute coronary syndrome (NONSTEMI), a clear 
J-shaped correlation was found between resting heart 
and all-cause mortality.5 The lowest mortality rate were in 
patients with resting heart rates between 50 and 70 beats 
per minute, but mortality doubled when heart rate was 
below 50 beats/minutes. 
Mortality was the lowest with a heart rate 50–60 beats/
minute without beta-blockers, but doubled when heart rate 
reduction was achieved with beta-blockers in this group. If 
heart rate was < 100 beats/minute, reduction of heart rate 
with beta-blockers reduced mortality. Natural tachycardia 
(>100 beats/minute) was associated with an increase in 
mortality.
Heart rate in prediction scores
Resting heart rate is included in risk assessment for patients 
after acute coronary syndromes e.g. the Global Registry 
of Acute Coronary events (GRACE) risk prediction score. 
Heart rate, however, is not included in some widely used 
risk scores for cardiovascular disease.
The problem
Lowering heart rate could reduce mortality and so could 
lower cardiovascular events, but this has not been 
specifically investigated, because drugs that lower heart 
rate such as beta-blockers and non-dehydropyridine 
calcium channel blockers have also other cardiovascular 
actions that confound the results.
Effects on mortality reduction of beta-blockers among 
patients with acute myocardial infarction or heart failure 
have been amply demonstrated. 
This reduction in mortality could at least in part be associated 
with the drug-mediated heart rate reduction, but beta-
blockers have numerous other actions, some beneficial, 
some undesirable. Although the association of heart rate 
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and cardiovascular outcome is suggestive, it does not, by 
itself, prove causality.
Is there an optimal heart rate
Although heart rate varies widely, there is a pattern of 
distribution in different populations with segregated heart 
rate values of between 75 beats/minute and 85 beats/
minute. From epidemiological data, it seems desirable 
to maintain heart rate in the normal rather then the high 
range. There seems to be a continuous increase in risk with 
increasing heart rate, at least for values above 60 beats/
minute with no evidence of a threshold.
Role of a specific heart-rate lowering 
drug: Ivabradine
Ivabradine is a specific inhibitor of the If current in the 
sinoatrial node and is a pure heart-rate lowering agent 
in patients with sinus rhythm. Clinical investigation into 
heart-rate reduction is now possible with ivabradine. The 
antianginal and anti-ischaemic efficacy of ivabradine in 
patients was demonstrated in controlled clinical trials 
previously. In everyday practice, in the REDUCTION study, 
four months treatment of ivabradine in angina patients 
was associated with a reduction in heart rate, a reduction 
in angina pectoris attacks, a reduction in consumption of 
short-acting nitrates and was well tolerated.6 Heart rate 
reduction by ivabradine in the ASSOCIATE study produced 
similar results.7 This specific heart rate lowering drug has 
demonstrated the clinical benefit of specific heart rate 
lowering in the symptomatology of coronary artery disease 
patients. Ivabradine has a beneficial effect on ischaemia-
related symptoms.7
In the BEAUTIFUL trial, the use of ivabradine in patients 
with coronary artery disease and a reduced left ventricular 
ejection fraction, when the heart rate was above 70/minute, 
reduced the secondary end points of admission to hospital 
with fatal and non-fatal myocardial infarctions and coronary 
revascularisations.8
Conclusion
The first well-established concept is that in the community, 
an increased resting heart rate is predictive of mortality 
and cardiovascular events and this association has no 
demonstrable threshold. Naturally occurring lower heart 
rates in the population at large are associated with improved 
general health (physical activity, not smoking, normal 
weight, healthy eating habits). 
The next concept is that an increased heart rate is 
predictive of mortalility in cardiovascular diseases such as 
hypertension, heart failure and angina pectoris. A partial 
explanation of mortality reduction with beta-blockers for 
instance, relates to heart rate lowering. In patients with stable 
coronary artery disease, the relationship between elevated 
heart rate and long-term cardiovascular outcome is linear. 
Also, the specific heart-rate lowering drug, ivabradine, 
when used in stable coronary artery disease with angina, 
reduces ischaemic pain and reduces myocardial infarctions 
and revascularisations. 
The next concept is the role of heart rate in acute coronary 
syndromes. With acute coronary events, heart rate on 
admission has a j-curve distribution in association with 
mortality. Heart rates at the extremes (< 50 beats/minute 
and > 100 beats/minute) are associated with poor in-
hospital outcome in acute coronary events. Drug-lowering 
therapy achieving a heart rate of < 70 beats/minute but > 50 
beats/minute will reduce patient mortality. All indications are 
that we should maybe start to pay more attention to resting 
heart rate in cardiovascular medicine as heart rate is indeed 
an independent risk factor.
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